Vascular function in rheumatoid arthritis: Intermediate phenotypes and cardiovascular risk

Journal of Hypertension

Volumn 25, Issue 6, 2007, Pages 1195-1196

  Delles, Christian ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; DRUG EFFECT; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 34250341713     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280dd8a77     Document Type: Editorial

References (26)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903-911.
2. Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am 1990; 16:513-537.
3. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44:2737-2745.
4. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107:1303-1307.
5. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37:481-494.
6. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM, Matteson EL. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48:54-58.
7. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50:3444-3449.
8. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108:2957-2963.
9. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005; 111:204-211.
10. Firuzi O, Fuksa L, Spadaro C, Bousova I, Riccieri V, Spadaro A, et al. Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 2006; 58:951-957.
11. Ozkan Y, Yardym-Akaydyn S, Sepici A, Keskin E, Sepici V, Simsek B. Oxidative status in rheumatoid arthritis. Clin Rheumatol 2007; 26:64-68.
12. Haruna Y, Morita Y, Komai N, Yada T, Sakuta T, Tomita N, et al. Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. Arthritis Rheum 2006; 54:1847-1855.
13. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 101:2206-2212.
14. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105:1656-1662.
15. Hamilton CA, Miller WH, Al-Benna S, Brosnan MJ, Drummond RD, McBride MW, Dominiczak AF. Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond) 2004; 106:219-234.
16. Delles C, Dominiczak AF. Vascular failure or sick vessel syndrome: the cardiovascular continuum is a useful concept for clinical research. J Hypertens 2006; 24:2147-2148.
17. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki-Jarvinen H. Impaired responsiveness toNOin newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002; 22:1637-1641.
18. Mäki-Petäjä KM, Hall FC, Booth AD, Wallace SML, Yasmin, Bearcroft PWP, et al. Rheumatoid arthritis is associated with increased aortic pulse wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006; 114:1185-1192.
19. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144:249-256.
20. Arosio E, De Marchi S, Rigoni A, Prior M, Lechi A. Forearm haemodynamics, arterial stiffness and micro-circulatory reactivity in rheumatoid arthritis. J Hypertens 2007; 25:1273-1278.
21. Herrera J, Ferrebuz A, Macgregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 2006; 17 (Suppl 3):S218-S225.
22. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004; 110:1774-1779.
23. Hermann F, Forster A, Chenevard R, Enseleit F, Hurlimann D, Corti R, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005; 45:461-464.
24. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015-2021.
25. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-1177.
26. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32:1213-1218.